C1QTNF9B encodes CTRP9 (C1q/TNF-related protein 9), a newly discovered adipokine that functions as the closest paralog of adiponectin 1. CTRP9 undergoes proteolytic cleavage to release its globular domain (gCTRP9), which serves as the major circulatory isoform and binds to adiponectin receptor 1 (AdipoR1) and N-cadherin to activate diverse signaling pathways 1. The protein regulates glucose and lipid metabolism, vascular relaxation, and cell differentiation 1. CTRP9 demonstrates significant cardiovascular protective effects by modulating multiple pathological processes in atherosclerosis, including inflammation, foam cell formation, endothelial dysfunction, insulin resistance, and vascular smooth muscle cell functions 1. Circulating CTRP9 levels are decreased in patients with coronary atherosclerosis disease 1. Beyond cardiovascular effects, C1QTNF9B has clinical relevance in cancer prognosis, being identified as part of a multidimensional transcriptome signature for bladder cancer survival prediction 2. CRISPR-Cas9 screening identified C1QTNF9B as a potential tumor suppressor, with its knockout enhancing prostate cancer cell invasion and metastasis 3. Additionally, genetic variants in the C1QTNF9B locus at 13q12.12 are significantly associated with high myopia in Han Chinese populations 4.